Limits...
Troponin and anti-troponin autoantibody levels in patients with ventricular noncompaction.

Erer HB, Güvenç TS, Kemik AS, Yılmaz HY, Kul Ş, Altay S, Sayar N, Kaya Y, Eren M - PLoS ONE (2013)

Bottom Line: Depending on ejection fraction, patients were grouped into noncompaction with preserved EF (LVEF >50%, n = 24) and noncompaction with reduced EF (LVEF <35%, n = 26) groups.Troponin I, troponin T, anti-troponin I IgM and anti-troponin T IgM were measured with sandwich immunoassay method using a commercially available kit.Patients with noncompaction had significantly higher troponin I (28.98±9.21 ng/ml in NCNE group and 28.11±10.42 ng/ml in NCLE group), troponin T (22.17±6.97 pg/ml in NCNE group and 22.78±7.76 pg/ml in NCLE group) and antitroponin I IgM (1.92±0.43 µg/ml in NCNE group and 1.79±0.36 µg/ml in NCLE group) levels compared to control group, while antitroponin T IgM and IgG were only elevated in patients with noncompaction and reduced EF (15.81±6.52 µg/ml for IgM and 16.46±6.25 µg/ml for IgG).

View Article: PubMed Central - PubMed

Affiliation: Dr. Siyami Ersek Cardiovascular and Thoracic Surgery Research and Training Hospital, Department of Cardiology, İstanbul, Turkey.

ABSTRACT
Ventricular hypertrabeculation/noncompaction is a morphologic and functional anomaly of myocardium characterized by prominent trabeculae accompanied by deep recessus. Dilated cardiomyopathy with left ventricular failure is observed in these patients, while the cause or pathophysiologic nature of this complication is not known. Anti-troponin antibodies are formed against circulating cardiac troponins after an acute coronary event or conditions associated with chronic myocyte necrosis, such as dilated cardiomyopathy. In present study, we aimed to investigate cardiac troponins and anti troponin autoantibodies in ventricular noncompaction/hypertrabeculation patients with/without reduced ejection fraction. A total of 50 patients with ventricular noncompaction and 23 healthy volunteers were included in this study. Noncompaction/hypertrabeculation was diagnosed with two-dimensional echocardiography using appropriate criteria. Depending on ejection fraction, patients were grouped into noncompaction with preserved EF (LVEF >50%, n = 24) and noncompaction with reduced EF (LVEF <35%, n = 26) groups. Troponin I, troponin T, anti-troponin I IgM and anti-troponin T IgM were measured with sandwich immunoassay method using a commercially available kit. Patients with noncompaction had significantly higher troponin I (28.98±9.21 ng/ml in NCNE group and 28.11±10.42 ng/ml in NCLE group), troponin T (22.17±6.97 pg/ml in NCNE group and 22.78±7.76 pg/ml in NCLE group) and antitroponin I IgM (1.92±0.43 µg/ml in NCNE group and 1.79±0.36 µg/ml in NCLE group) levels compared to control group, while antitroponin T IgM and IgG were only elevated in patients with noncompaction and reduced EF (15.81±6.52 µg/ml for IgM and 16.46±6.25 µg/ml for IgG). Elevated cardiac troponins and anti-troponin I autoantibodies were observed in patients with noncompaction preceding the decline in systolic function and could indicate ongoing myocardial damage in these patients.

Show MeSH

Related in: MedlinePlus

Scatter plot diagrams showing relationship between ejection fraction and antitroponin I IgM, antitroponin T IgM and antitroponin T IgG in noncompaction patients.Correlations for antitroponin I IgM (A), antitroponin T IgM (B) and antitroponin T IgG (C) did not reach statistical significance and had low correlation coefficients. Note that antitroponin T IgM levels were similar to antitroponin T IgG levels (in panels B and C).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585198&req=5

pone-0057648-g003: Scatter plot diagrams showing relationship between ejection fraction and antitroponin I IgM, antitroponin T IgM and antitroponin T IgG in noncompaction patients.Correlations for antitroponin I IgM (A), antitroponin T IgM (B) and antitroponin T IgG (C) did not reach statistical significance and had low correlation coefficients. Note that antitroponin T IgM levels were similar to antitroponin T IgG levels (in panels B and C).

Mentions: Troponin I and antitroponin I IgM levels showed a significant correlation with each other (r = 0.696, p<0.001); while both parameters did not show a significant correlation with LVEF, LVEDv or LVESv in noncompaction patients. Troponin T did not correlate with antitroponin T IgM or IgG levels (r = −0.087, p>0.05 for IgM and r = −0.057, p>0.05 for IgG), and both parameters lacked a significant correlation with LVEF, LVEDv or LVESv in noncompaction patients (Figure 3). No significant correlation was observed between cTnI, cTnT, anti-cTnI IgM, anti-cTnT IgM or anti-cTnT IgG levels and number of segments with hypertrabeculation/noncompaction.


Troponin and anti-troponin autoantibody levels in patients with ventricular noncompaction.

Erer HB, Güvenç TS, Kemik AS, Yılmaz HY, Kul Ş, Altay S, Sayar N, Kaya Y, Eren M - PLoS ONE (2013)

Scatter plot diagrams showing relationship between ejection fraction and antitroponin I IgM, antitroponin T IgM and antitroponin T IgG in noncompaction patients.Correlations for antitroponin I IgM (A), antitroponin T IgM (B) and antitroponin T IgG (C) did not reach statistical significance and had low correlation coefficients. Note that antitroponin T IgM levels were similar to antitroponin T IgG levels (in panels B and C).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585198&req=5

pone-0057648-g003: Scatter plot diagrams showing relationship between ejection fraction and antitroponin I IgM, antitroponin T IgM and antitroponin T IgG in noncompaction patients.Correlations for antitroponin I IgM (A), antitroponin T IgM (B) and antitroponin T IgG (C) did not reach statistical significance and had low correlation coefficients. Note that antitroponin T IgM levels were similar to antitroponin T IgG levels (in panels B and C).
Mentions: Troponin I and antitroponin I IgM levels showed a significant correlation with each other (r = 0.696, p<0.001); while both parameters did not show a significant correlation with LVEF, LVEDv or LVESv in noncompaction patients. Troponin T did not correlate with antitroponin T IgM or IgG levels (r = −0.087, p>0.05 for IgM and r = −0.057, p>0.05 for IgG), and both parameters lacked a significant correlation with LVEF, LVEDv or LVESv in noncompaction patients (Figure 3). No significant correlation was observed between cTnI, cTnT, anti-cTnI IgM, anti-cTnT IgM or anti-cTnT IgG levels and number of segments with hypertrabeculation/noncompaction.

Bottom Line: Depending on ejection fraction, patients were grouped into noncompaction with preserved EF (LVEF >50%, n = 24) and noncompaction with reduced EF (LVEF <35%, n = 26) groups.Troponin I, troponin T, anti-troponin I IgM and anti-troponin T IgM were measured with sandwich immunoassay method using a commercially available kit.Patients with noncompaction had significantly higher troponin I (28.98±9.21 ng/ml in NCNE group and 28.11±10.42 ng/ml in NCLE group), troponin T (22.17±6.97 pg/ml in NCNE group and 22.78±7.76 pg/ml in NCLE group) and antitroponin I IgM (1.92±0.43 µg/ml in NCNE group and 1.79±0.36 µg/ml in NCLE group) levels compared to control group, while antitroponin T IgM and IgG were only elevated in patients with noncompaction and reduced EF (15.81±6.52 µg/ml for IgM and 16.46±6.25 µg/ml for IgG).

View Article: PubMed Central - PubMed

Affiliation: Dr. Siyami Ersek Cardiovascular and Thoracic Surgery Research and Training Hospital, Department of Cardiology, İstanbul, Turkey.

ABSTRACT
Ventricular hypertrabeculation/noncompaction is a morphologic and functional anomaly of myocardium characterized by prominent trabeculae accompanied by deep recessus. Dilated cardiomyopathy with left ventricular failure is observed in these patients, while the cause or pathophysiologic nature of this complication is not known. Anti-troponin antibodies are formed against circulating cardiac troponins after an acute coronary event or conditions associated with chronic myocyte necrosis, such as dilated cardiomyopathy. In present study, we aimed to investigate cardiac troponins and anti troponin autoantibodies in ventricular noncompaction/hypertrabeculation patients with/without reduced ejection fraction. A total of 50 patients with ventricular noncompaction and 23 healthy volunteers were included in this study. Noncompaction/hypertrabeculation was diagnosed with two-dimensional echocardiography using appropriate criteria. Depending on ejection fraction, patients were grouped into noncompaction with preserved EF (LVEF >50%, n = 24) and noncompaction with reduced EF (LVEF <35%, n = 26) groups. Troponin I, troponin T, anti-troponin I IgM and anti-troponin T IgM were measured with sandwich immunoassay method using a commercially available kit. Patients with noncompaction had significantly higher troponin I (28.98±9.21 ng/ml in NCNE group and 28.11±10.42 ng/ml in NCLE group), troponin T (22.17±6.97 pg/ml in NCNE group and 22.78±7.76 pg/ml in NCLE group) and antitroponin I IgM (1.92±0.43 µg/ml in NCNE group and 1.79±0.36 µg/ml in NCLE group) levels compared to control group, while antitroponin T IgM and IgG were only elevated in patients with noncompaction and reduced EF (15.81±6.52 µg/ml for IgM and 16.46±6.25 µg/ml for IgG). Elevated cardiac troponins and anti-troponin I autoantibodies were observed in patients with noncompaction preceding the decline in systolic function and could indicate ongoing myocardial damage in these patients.

Show MeSH
Related in: MedlinePlus